参考文献/References:
[1] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66(2):115-132. DOI:10.3322/caac.21338.
[2] 支修益, 石远凯, 于金明.中国原发性肺癌诊疗规范(2015年版)[J].中华肿瘤杂志, 2015, 37(1):67-78. DOI:10.3760/cma.j.issn.0253-3766.2015.01.014.Zhi XY, Shi YK, Yu JM.Standards for the diagnosis and treatment of primary lung cancer(2015 version) in China[J].Chin J Oncol, 2015, 37(1):67-78.
[3] 孙志超, 吴仪仪, 余仲飞, 等.增强CT与PET/CT在诊断肺癌及其淋巴结转移中的价值[J].医学研究杂志, 2014, 43(10):42-45.Sun ZC, Wu YY, Yu ZF, et al.Evaluation of enhancement CT combined with PET/CT in diagnosis of lung cancer and lymph node[J].J Med Res, 2014, 43(10):42-45.
[4] 吴仪仪, 张建, 左长京, 等.PET/CT与增强CT对肺癌淋巴结诊断及分期的比较[J].临床肺科杂志, 2014, 19(10):1846-1848. DOI:10.3969/j.issn.1009-6663.2014.010.035.Wu YY, Zhang J, Zuo CJ, et al.Comparison of nodal staging between PET/CT and CECT in patient with lung cancer[J].J Clin Pulmonary Med, 2014, 19(10):1846-1848.
[5] Lee PC, Port JL, Korst RJ, et al.Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer[J].Ann Thorac Surg, 2007, 84(1):177-181. DOI:10.1016/j.athoracsur.2007.03.081.
[6] Higashi K, Ito K, Hiramatsu Y, et al.18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer:analysis of a multicenter study[J].J Nucl Med, 2005, 46(2):267-273.
[7] Park HK, Jeon K, Koh WJ, et al.Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT[J].Respirology, 2010, 15(8):1179-1184. DOI:10.1111/j.1440-1843.2010.01793.x.
[8] Miyasaka Y, Suzuki K, Takamochi K, et al.The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer[J].Eur J Cardiothorac Surg, 2013, 44(1):83-87. DOI:10.1093/ejcts/ezs604.
[9] Zhao L, He ZY, Zhong XN, et al.18FDG-PET/CT for detection of mediastinal nodal metastasis in non-small cell lung cancer:A meta-analysis[J].Surg Oncol, 2012, 21(3):230-236. DOI:10.1016/j.suronc.2011.11.001.
[10] Lv YL, Yuan DM, Wang K, et al.Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer a bivariate systematic review and Meta-Analysis[J].J Thorac Oncol, 2011, 6(8):1350-1358. DOI:10.1097/JTO.0b013e31821d4384.
[11] Al-Jahdali H, Khan AN, Loutfi S, et al.Guidelines for the role of FDG-PET/CT in lung cancer management[J].J Infect Public Health, 2012, 5 Suppl 1:S35-S40. DOI:10.1016/j.jiph.2012.09.003.
[12] Wu Y, Li P, Zhang H, et al.Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients[J/OL].Int J Cancer, 2013, 132(2):E37-47[2016-08-08].https://www.ncbi.nlm.nih.gov/pubmed/22890912. DOI:10.1002/ijc.27779.
[13] Bryant AS, Cerfolio RJ, Klemm KM, et al.Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer[J].Ann Thorac Surg, 2006, 82(2):417-423.
[14] Tasci E, Tezel C, Orki A, et al.The role of integrated positron emission tomography and computed tomography in the assessment of nodal spread in cases with non-small cell lung cancer[J].Interact Cardiovasc Thorac Surg, 2010, 10(2):200-203. DOI:10.1510/icvts.2009.220392.
[15] Tournoy KG, Maddens S, Gosselin R, et al.Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant:a prospective study[J].Thorax, 2007, 62(8):696-701. DOI:10.1136/thx.2006.072959.
[16] Kang WJ, Chung JK, So Y, et al.Differentiation of mediastinal FDG uptake observed in patients with non-thoracic tumours[J].Eur J Nucl Med Mol Imaging, 2004, 31(2):202-207. DOI:10.1007/s00259-003-1368-x.
[17] Lee J, Aronchick JM, Alavi A.Accuracy of 18F fluorodeoxyglucose positron emission tomography for the evaluation malignancy in patients presenting with new lung abnormalities-A retrospective review[J].Chest, 2001, 120(6):1791-1797. DOI:10.1378/chest.120.6.1791.
[18] 段晓蓓, 樊卫, 许泽清, 等.最大标准摄取值诊断非小细胞肺癌纵隔淋巴结转移的最佳界值[J].中国医学影像技术, 2012, 28(5):916-920.Duan XB, Fan W, Xu ZQ, et al.Optimal threshold in diagnosing mediastinal lymph node metastasis of non-small cell lung cancer with maximum standardized uptake value[J].Chin J Med Imaging Technol, 2012, 28(5):916-920.
[19] 马文超, 徐文贵, 朱湘, 等.18F-FDG PET/CT SUVmax及CT值双定量分析在肺癌纵隔淋巴结鉴别诊断中的价值[J].中国肿瘤临床, 2011, 38(5):284-287. DOI:10.3969/j.issn.1000-8179.2011.05.011.Ma WC, Xu WG, Zhu X, et al.Differential diagnosis of mediastinal lymph node metastasis in lung cancer patients using 18F-FDG PET/CT with double quantitative SUVmax and CT value[J].Chin J Clin Oncol, 2011, 38(5):284-287.
[20] 叶鹏飞, 韩星敏, 谢新立, 等.纵隔淋巴结与原发灶最大标准摄取值比值对非小细胞肺癌纵隔淋巴结转移的诊断价值[J].中国医学影像技术, 2014, 30(12):1839-1843.Ye PF, Han XM, Xie XL, et al.Maximum standardized uptake value ratio of mediastinal lymph node to primary tumor in diagnosis of mediastinal lymph node metastasis in patients with non-small cell lung cancer[J].Chin J Med Imaging Technol, 2014, 30(12):1839-1843.
[21] Koksal D, Demirag F, Bayiz H, et al.The correlation of SUVmax with pathological characteristics of primary tumor and the value of Tumor/Lymph node SUVmax ratio for predicting metastasis to lymph nodes in resected NSCLC patients[J/OL].J CardiothoracSurg, 2013, 8:63[2016-08-08].https://www.ncbi.nlm.nih.gov/pubmed/?term=23557204. DOI:10.1186/1749-8090-8-63.
[22] Honguero Martínez AF, García Jiménez MD, García Vicente A, et al.Ratio between maximum standardized uptake value of N1 lymph nodes and tumor predicts N2 disease in patients with non-small cell lung cancer in 18F-FDG PET-CT scan[J].Rev Esp Med Nucl Imagen Mol, 2016, 35(3):159-164. DOI:10.1016/j.remn.2015.08.004.
[23] Kuo WH, Wu YC, Wu CY, et al.Node/aorta and node/liver SUV ratios from 18F-FDG PET/CT may improve the detection of occult mediastinal lymph node metastases in patients with non-small cell lung carcinoma[J].Acad Radiol, 2012, 19(6):685-692. DOI:10.1016/j.acra.2012.02.013.
[24] Hu M, Han A, Xing L, et al.Value of dual-time-point FDG PET/CT for mediastinal nodal staging in non-small-cell lung cancer patients with lung comorbidity[J].Clin Nucl Med, 2011, 36(6):429-433. DOI:10.1097/RLU.0b013e3182173810.
[25] Kim DW, Kim WH, Kim CG.Dual-time-point FDG PET/CT:Is It Useful for Lymph Node Staging in Patients with Non-Small-Cell Lung Cancer?[J].Nucl Med Mol Imaging, 2012, 46(3):196-200. DOI:10.1007/s13139-012-0141-0.
[26] Kasai T, Motoori K, Horikoshi T, et al.Dual-time point scanning of integrated FDG PET/CT for the evaluation of mediastinal and hilar lymph nodes in non-small cell lung cancer diagnosed as operable by contrast-enhanced CT[J].Eur J Radiol, 2010, 75(2):143-146. DOI:10.1016/j.ejrad.2009.04.044..
[27] Wu LM, Xu JR, Gu HY, et al.Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer:which is better?[J].J Surg Res, 2012, 178(1):304-314. DOI:10.1016/j.jss.2012.03.074.
[28] Schaarschmidt BM, Buchbender C, Nensa F, et al.Correlation of the apparent diffusion coefficient(ADC) with the standardized uptake value(SUV) in lymph node metastases of non-small cell lung cancer(NSCLC) patients using hybrid 18F-FDG PET/MRI[J/OL].PLoS One, 2015, 10(1):e0116277[2016-08-08].https://www.ncbi.nlm.nih.gov/pubmed/?term=25793286. DOI:10.1371/journal.pone.0120606.
[29] Huellner MW, de Galiza Barbosa F, Husmann L, et al.TNM Staging of Non-Small Cell Lung Cancer:Comparison of PET/MR and PET/CT[J].J Nucl Med, 2016, 57(1):21-26. DOI:10.2967/jnumed.115.162040.
[30] Kohan AA, Kolthammer JA, Vercher-Conejero JL, et al.N staging of lung cancer patients with PET/MRI using a three-segment model attenuation correction algorithm:Initial experience[J].EurRadiol, 2013, 23(11):3161-3169. DOI:10.1007/s00330-013-2914-y.
[31] Schwenzer NF, Schraml C, Müller M, et al.Pulmonary lesion assessment:comparison of whole-body hybrid MR/PET and PET/CT imaging——pilot study[J].Radiology, 2012, 264(2):551-558. DOI:10.1148/radiol.12111942.
[32] Herbrik M, Treffert J, Geiger B, et al.Diagnostic accuracy of virtual 18F-FDG PET/CT bronchoscopy for the detection of lymph node metastases in non-small cell lung cancer patients[J].J Nucl Med, 2011, 52(10):1520-1525. DOI:10.2967/jnumed.111.092593.
[33] Buchbender C, Herbrik M, Treffert JA, et al.Virtual 18F-FDG PET/CT bronchoscopy for lymph node staging in non-small-cell lung cancer patients:present and future applications[J].Expert Rev Med Devices, 2012, 9(3):241-247. DOI:10.1586/ERD.12.9.
[34] Lasnon C, Hicks RJ, Beauregard J, et al.Impact of point spread function Reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in Non-Small cell lung cancer[J].Clin Nucl Med, 2012, 37(10):971-976. DOI:10.1097/RLU.0b013e318251e3d1.
相似文献/References:
[1]李景涛,邓垒,张文珏,等.广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析[J].国际放射医学核医学杂志,2016,40(2):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
Li Jingtao,Deng Lei,Zhang Wenjue,et al.Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
[2]万绪明,许祖闪,侯红军.磁共振表观弥散系数变化率对肝细胞肝癌患者单次TACE术后疗效评价的应用价值[J].国际放射医学核医学杂志,2015,39(2):129.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
Wan Xuming,Xu Zushan,Hou Hongjun.Applieation value of the change ratio of apparent diffusion coefficient in the therapeutic evaluation of hepatocellular carcinoma treated by single transcatheter arterial chemoembolization[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):129.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
[3]王振光,王洋洋.PET/CT显像在肝细胞肝癌诊断中的研究进展[J].国际放射医学核医学杂志,2015,39(2):175.[doi:10.3760/cma.j.issn.1673-4114.2015.02.016]
Wang Zhenguang,Wang Yangyang.The development of PET/CT imaging in the diagnosis of hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):175.[doi:10.3760/cma.j.issn.1673-4114.2015.02.016]
[4]李欢欢,李素平,游金辉.小细胞肺癌伴副肿瘤综合征患者骨显像示肌肉摄取一例[J].国际放射医学核医学杂志,2014,38(2):140.[doi:10.3760/cma.j.issn.1673-4114.2014.02.016]
[5]龙再颖,汤春静,于立明,等.甲状腺乳头状癌术后刺激状态Tg与颈部淋巴结转移关系的研究[J].国际放射医学核医学杂志,2013,37(1):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
LONG Zai-ying,TANG Chun-jing,YU Li-ming,et al.The correlation between the stimulated thyroglobulin level after surgery in papillary thyroid carcinoma and cervical lymph node metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
[6]张一秋,石洪成.肝细胞癌肿瘤新生血管影像学评价的研究进展[J].国际放射医学核医学杂志,2013,37(1):60.[doi:10.3760/cma.j.issn.1673-4114.2013.01.015]
ZHANG Yi-qiu,SHI Hong-cheng.Advances in assessment of imaging examination for tumor neoangiogenesis induced by hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):60.[doi:10.3760/cma.j.issn.1673-4114.2013.01.015]
[7]任凌,戴皓洁.125Ⅰ粒子在头颈部腺样囊性癌综合治疗中的作用[J].国际放射医学核医学杂志,2011,35(1):13.[doi:10.3760/cma.j.issn.1673-4114.2011.01.004]
REN Ling,DAI Hao-jie.The effect of 125I seed in comprehensive therapy of the head and neck adenoid cystic carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):13.[doi:10.3760/cma.j.issn.1673-4114.2011.01.004]
[8]李红兵,陈勇,曾建国,等.肝动脉化疗性栓塞结合Ⅱ期手术切除治疗巨块型外生型肝癌[J].国际放射医学核医学杂志,2010,34(1):49.[doi:10.3760/cma.j.issn.1673-4114.2010.01.013]
LI Hong-bing,CHEN Yong,ZENG Jian-guo,et al.Treatment of massive extrahepatic growing hepatocellular carcinoma with TACE in combination with secondary resection[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(6):49.[doi:10.3760/cma.j.issn.1673-4114.2010.01.013]
[9]付晓昉,王秀梅,许建春.放射性榄香烯三羰基铼配合物在荷小细胞肺癌裸鼠体内的分布及其对肿瘤的生长抑制作用[J].国际放射医学核医学杂志,2009,33(6):335.[doi:10.3760/cma.j.issn.1673-4114.2009.06.004]
FU Xiao-fang,WANG Xiu-mei,XU Jian-chun.Anti-tumor effect of elemene tricarbonyl rhenium-188 complex to small cell lung cancer and its biodistribution in nude mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(6):335.[doi:10.3760/cma.j.issn.1673-4114.2009.06.004]
[10]郑磊,李前伟.18F-氟脱氧葡萄糖PET在原发陛肝细胞癌中的应用[J].国际放射医学核医学杂志,2008,32(1):23.
ZHENG Lei,LI Qian-wei.Application of positron emission tomography with 18F-fluorodeoxyglucose in hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(6):23.
[11]戈畅,梁硕.化疗联合DC-CIK生物治疗非小细胞肺癌的临床价值及CT灌注成像的疗效评价[J].国际放射医学核医学杂志,2014,38(6):377.[doi:10.3760/cma.j.issn.1673-4114.2014.06.007]
Ge Chang,Liang Shuo.The clinical value and CT perfusion evaluation in chemotherapy combined with DC-CIK biological treatment of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):377.[doi:10.3760/cma.j.issn.1673-4114.2014.06.007]
[12]黄少祥,樊体强.塞来昔布对非小细胞肺癌移植瘤的辐射增敏实验研究[J].国际放射医学核医学杂志,2013,37(3):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
HUANG Shao-xiang,FAN Ti-qiang.Radiosensitization on non-small cell lung cancer induced by celecoxib[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
[13]于丽娟,李迎辞,王文志,等.PET-CT及PET-CT结合Lung VCAR软件对非小细胞肺癌肺门区淋巴结的诊断分析[J].国际放射医学核医学杂志,2012,36(6):323.[doi:10.3760/cma.j.issn.1673-4114.2012.06.002]
YU Li-juan,LI Ying-ci,WANG Wen-zhi,et al.Value of PET-CT and PET-CT combined with Lung VCAR software in the diagnosis of hilar area lymph nodes of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):323.[doi:10.3760/cma.j.issn.1673-4114.2012.06.002]
[14]刘莉,杨景魁.125I粒子植入治疗非小细胞肺癌的护理及辐射防护[J].国际放射医学核医学杂志,2012,36(3):172.[doi:10.3760/cma.j.issn.1673-4114.2012.03.013]
LIU Li,YANG Jing-kui.Radiation protective nursing intervene of 125I seed implantation in non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):172.[doi:10.3760/cma.j.issn.1673-4114.2012.03.013]
[15]梁吉祥,柴树德,郑广钧,等.CT引导下植入125I粒子治疗非小细胞肺癌切除术后局部复发的疗效[J].国际放射医学核医学杂志,2011,35(3):181.[doi:10.3760/cma.j.issn.1673-4114.2011.03.012]
LIANG Ji-xiang,CHAI Shu-de,ZHENG Guang-jun,et al.CT-guided percutaneous interstitial implantation of 125I for recurrent patients of postoperative non-small cell lung carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):181.[doi:10.3760/cma.j.issn.1673-4114.2011.03.012]
[16]吴红宇,贺晓东,刘宇,等.呼吸门控放疗非小细胞肺癌[J].国际放射医学核医学杂志,2011,35(5):314.[doi:10.3760/cma.j.issn.1673-4114.2011.05.015]
WU Hong-yu,HE Xiao-dong,LIU Yu,et al.Respiratory gated radiotherapy for non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):314.[doi:10.3760/cma.j.issn.1673-4114.2011.05.015]
[17]陆光兵,刘丽.125I粒子联合EP方案治疗局部晚期非小细胞肺癌的临床分析[J].国际放射医学核医学杂志,2010,34(2):105.[doi:10.3760/cma.j.issn.1673-4114.2010.02.012]
[18]鲁胜男,冯彦林.18F-FDG PET-CT在评价肺癌化疗疗效中的应用[J].国际放射医学核医学杂志,2010,34(3):164.
LU Sheng-nan,FENG Yan-lin.The application of 18F-FDG PET-CT in evaluation of the value of lung cancer chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(6):164.
[19]姚立新,付占昭,顾涛,等.99Tcm-甲氧基异丁基异腈SPECT评价非小细胞肺癌化疗疗效[J].国际放射医学核医学杂志,2009,33(5):272.[doi:10.3760/cnla.j.issn.1673-4114.2009.05.005]
YAO Li-xin,FU Zhan-zhao,GU Tao,et al.99Tcm-methoxyisobutylisonitrile SPECT imaging evaluate chemotherapy of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(6):272.[doi:10.3760/cnla.j.issn.1673-4114.2009.05.005]
[20]付丽,张遵城,于兆晨,等.CT引导125I粒子治疗非小细胞肺癌的辐射防护护理干预[J].国际放射医学核医学杂志,2009,33(5):312.[doi:10.3760/cnla.j.issn.1673-4114.2009.05.018]
FU Li,ZHANG Zun-cheng,YU Zhao-chen,et al.Radiation protective nursing intervene of 125I seed implantation in non-small cell lung carcinoma guided by CT[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(6):312.[doi:10.3760/cnla.j.issn.1673-4114.2009.05.018]